Penumbra, Inc. PEN reported first-quarter 2025 adjusted earnings per share (EPS) of 83 cents, which surpassed the Zacks ...

Researchers compared outcomes associated with conventional excision vs Mohs micrographic surgery among patients with hand and foot melanoma.

Analysts have set 12-month price targets for Penumbra, revealing an average target of $313.83, a high estimate of $340.00, ...

Q1 2025 Earnings Call Transcript April 23, 2025 Boston Scientific Corporation beats earnings expectations. Reported EPS is $0 ...

Q1 2025 thrombectomy revenue reached $226.5 million, an increase of 20.7% year-over-year, with U.S. thrombectomy contributing significantly to this growth. International thrombectomy increased 3.3%, ...

Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ETCompany ParticipantsCecilia Furlong - Business Development & ...